PL2137192T3 - Pochodne galantaminy jako proleki do leczenia chorób mózgu u ludzi - Google Patents
Pochodne galantaminy jako proleki do leczenia chorób mózgu u ludziInfo
- Publication number
- PL2137192T3 PL2137192T3 PL08735211T PL08735211T PL2137192T3 PL 2137192 T3 PL2137192 T3 PL 2137192T3 PL 08735211 T PL08735211 T PL 08735211T PL 08735211 T PL08735211 T PL 08735211T PL 2137192 T3 PL2137192 T3 PL 2137192T3
- Authority
- PL
- Poland
- Prior art keywords
- galantamine
- pro
- drugs
- derivatives
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2008/002929 WO2009127218A1 (en) | 2008-04-14 | 2008-04-14 | Derivatives of galantamine as pro-drugs for the treatment of human brain diseases |
EP08735211.8A EP2137192B8 (en) | 2008-04-14 | 2008-04-14 | Derivatives of galantamine as pro-drugs for the treatment of human brain diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2137192T3 true PL2137192T3 (pl) | 2014-07-31 |
Family
ID=40019199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL08735211T PL2137192T3 (pl) | 2008-04-14 | 2008-04-14 | Pochodne galantaminy jako proleki do leczenia chorób mózgu u ludzi |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP2137192B8 (pl) |
JP (1) | JP5504253B2 (pl) |
CN (1) | CN102007129B (pl) |
CA (1) | CA2721007C (pl) |
DK (1) | DK2137192T3 (pl) |
ES (1) | ES2463715T3 (pl) |
PL (1) | PL2137192T3 (pl) |
WO (1) | WO2009127218A1 (pl) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014016430A1 (en) * | 2012-07-27 | 2014-01-30 | Neurodyn Life Sciences Inc. | Enhanced brain bioavailability of galantamine by selected formulations and transmucosal administration of lipophilic prodrugs |
PT3417862T (pt) | 2012-07-27 | 2021-08-06 | Neurodyn Life Sciences Inc | Biodisponibilidade cerebral da galantamina melhorada através de formulações selecionadas e administração transmucosal de pró-fármacos lipofílicos |
EP3122363B1 (en) * | 2014-03-25 | 2021-06-23 | Synaptec Development LLC | Galantamine carbamates for the treatment of autism |
JP6738797B2 (ja) * | 2014-03-25 | 2020-08-12 | イーエムアイシーアイピーアイ・エルエルシーEmicipi Llc | レット症候群治療薬 |
WO2015176069A2 (en) * | 2014-05-16 | 2015-11-19 | Synaptec Development Llc | CLEARANCE OF AMYLOID ß |
EP4029867A1 (en) | 2021-01-13 | 2022-07-20 | Alpha Cognition Inc. | Solid forms of galantamine benzoate gluconate |
EP4186509A1 (en) | 2021-11-26 | 2023-05-31 | Alpha Cognition Inc. | Alpha-1062 for treating traumatic brain injury |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6150354A (en) | 1987-01-15 | 2000-11-21 | Bonnie Davis | Compounds for the treatment of Alzheimer's disease |
JP2755403B2 (ja) | 1987-05-04 | 1998-05-20 | デイービス、ボニー | アルツハイマー病の治療のための化合物 |
US6316439B1 (en) | 1993-10-15 | 2001-11-13 | Aventis Pharamaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
US6323196B1 (en) | 1993-10-15 | 2001-11-27 | Aventis Pharmaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
US6323195B1 (en) | 1993-10-15 | 2001-11-27 | Aventis Pharmaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
AT403803B (de) | 1996-04-19 | 1998-05-25 | Sanochemia Ltd | Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln |
AU1282099A (en) * | 1997-10-29 | 1999-05-17 | Bonnie M. Davis | Method for treatment of disorders of attention |
AU1430099A (en) | 1998-12-01 | 2000-06-19 | Sanochemia Pharmazeutika Aktiengesellschaft | Use of galanthamine and galanthamine derivatives in the case of acute functionalbrain damage |
EP1237524A4 (en) | 1999-12-10 | 2004-06-30 | Bonnie M Davis | GALANTHAMINE AND LYCORAMINE ANALOGS FOR USE AS MODULATORS OF NICOTINIC RECEPTORS |
CN1380883A (zh) | 2000-03-31 | 2002-11-20 | 萨诺化学药物股份公司 | 雪花胺的新衍生物和类似物 |
US20030162770A1 (en) | 2002-02-22 | 2003-08-28 | Davis Bonnie M. | Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
CN1875004B (zh) | 2003-09-26 | 2010-06-23 | 台湾神隆股份有限公司 | 那维啶酰胺衍生物的拆分 |
AT414125B (de) | 2003-09-29 | 2006-09-15 | Sanochemia Pharmazeutika Ag | Neue derivate des 4a,5,9,10,11,12-hexahydro- benzofuro(3a,3,2)(2) benzazepin, verfahren zu deren herstellung sowie deren verwendung zur herstellung von arzneimitteln |
EP1777222A1 (en) | 2005-09-22 | 2007-04-25 | Galantos Pharma GmbH | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
-
2008
- 2008-04-14 ES ES08735211.8T patent/ES2463715T3/es active Active
- 2008-04-14 EP EP08735211.8A patent/EP2137192B8/en active Active
- 2008-04-14 CN CN200880128608.5A patent/CN102007129B/zh active Active
- 2008-04-14 PL PL08735211T patent/PL2137192T3/pl unknown
- 2008-04-14 CA CA2721007A patent/CA2721007C/en active Active
- 2008-04-14 WO PCT/EP2008/002929 patent/WO2009127218A1/en active Application Filing
- 2008-04-14 JP JP2011504317A patent/JP5504253B2/ja not_active Expired - Fee Related
- 2008-04-14 DK DK08735211.8T patent/DK2137192T3/da active
Also Published As
Publication number | Publication date |
---|---|
EP2137192B8 (en) | 2014-06-11 |
WO2009127218A1 (en) | 2009-10-22 |
CN102007129B (zh) | 2014-05-07 |
CN102007129A (zh) | 2011-04-06 |
JP5504253B2 (ja) | 2014-05-28 |
CA2721007A1 (en) | 2009-10-22 |
JP2011516588A (ja) | 2011-05-26 |
EP2137192B1 (en) | 2014-02-19 |
EP2137192A1 (en) | 2009-12-30 |
CA2721007C (en) | 2014-04-29 |
ES2463715T3 (es) | 2014-05-29 |
DK2137192T3 (da) | 2014-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2262508A4 (en) | SUBSTITUTED p-CHINONE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH OXIDATIVE STRESS | |
HK1163500A1 (en) | Pharmaceutical composition for the treatment of heart diseases | |
EP2187743A4 (en) | FORMULATIONS FOR THE TREATMENT OF DISEASES OR EYE DISORDERS | |
HK1154382A1 (en) | Triazole derivatives useful for the treatment of diseases | |
EP2166837A4 (en) | DRUG COMBINATION USEFUL FOR THE TREATMENT OF SKIN DISORDERS | |
EP2134173A4 (en) | TREATMENT OF DISEASES SIGNED BY IGNITION | |
IL208357A0 (en) | Spiro-indole derivatives for the treatment of parasitic diseases | |
EP2498796A4 (en) | TREATMENT OF HEART DISEASES | |
PT2049127E (pt) | Derivados n-metanocarba para tratamento de doenças cardíacas | |
GB2483419B (en) | Formulations for the treatment of deep tissue pain | |
IL211313A0 (en) | Compounds, compositions and methods for the treatment of ??-amyloid diseases and synucleinopathies | |
GB0906159D0 (en) | Drug combination for the treatment of proteostatic diseases | |
PL2137192T3 (pl) | Pochodne galantaminy jako proleki do leczenia chorób mózgu u ludzi | |
SI2605769T1 (sl) | Derivati benzokinona za zdravljenje mitohondrijskih očesnih bolezni | |
PL392436A1 (pl) | Pochodne arylosulfonamidów do leczenia chorób odśrodkowego układu nerwowego | |
IL225755A0 (en) | Amido-6 derivatives of epoxymorphinans-a5, 4 for the treatment of pain | |
IL213606A0 (en) | 1-amino-alkylcyclohexane derivatives for the treatment of inflamatory skin diseases | |
IL220134A0 (en) | Thiazole derivatives for the treatment of diseases such as cancer | |
IL209036A0 (en) | Device for stimulating areas of the human brain | |
GB0814043D0 (en) | The treatment of skin disorders | |
IL207753A0 (en) | Substituted 4-aminocyclohexane derivatives for the treatment of pain | |
GB0801511D0 (en) | The treatment of ophthalmic diseases | |
GB0716834D0 (en) | New formulation for treatment of skin disorders | |
GB0901727D0 (en) | The treatment of ophthalmic diseases | |
AU2008904641A0 (en) | Therapeutic breast health formula |